10-K: Scorpius Holdings Faces Delisting Amid Financial Struggles, Explores Strategic Alternatives

Scorpius Holdings grapples with NYSE American delisting, significant losses, and a search for strategic options as it navigates a challenging financial landscape.

Summary

• Scorpius Holdings, a contract development and manufacturing organization (CDMO), faces potential delisting from the NYSE American due to a low stock price and failure to meet filing deadlines.
• The company is exploring strategic alternatives and has engaged Alliance Global Partners to assist in the process.
• Scorpius has incurred net losses every year since its inception, with a net loss of $34.3 million in 2024 and an accumulated deficit of $287.2 million.
• The company's cash and short-term investments totaled approximately $1.2 million as of December 31, 2024, and are expected to fund operations only through April 2025.
• Scorpius is seeking additional funding through equity financings, debt financings, equipment sale leasebacks, and partnerships.
• The company's revenue decreased in 2024, primarily due to a customer migrating to a larger CDMO.
• Scorpius has identified material weaknesses in its internal control over financial reporting.
• The company's ability to continue as a going concern is uncertain.
• The company is focused on expanding its biomanufacturing capabilities and diversifying its customer base.
• The company has appointed Tan Sze Thuan to its Board of Directors to support international financing and expansion opportunities.

Sentiment

Score: 3

Explanation: The document paints a concerning picture of Scorpius Holdings' financial health and future prospects. The risk of delisting, ongoing losses, and need for additional funding create significant uncertainty. While the company is exploring strategic alternatives, the overall sentiment is negative.

Positives

• Scorpius is exploring strategic alternatives to improve its financial position.
• The company is focused on expanding its biomanufacturing capabilities and diversifying its customer base.
• The company has appointed Tan Sze Thuan to its Board of Directors to support international financing and expansion opportunities.
• The company is working to remediate material weaknesses in its internal control over financial reporting.

Negatives

• Scorpius Holdings is at risk of being delisted from the NYSE American due to a low stock price and failure to meet filing deadlines.
• The company reported a net loss of $34.3 million in 2024 and has an accumulated deficit of $287.2 million.
• The company's cash and short-term investments are expected to fund operations only through April 2025.
• Scorpius has identified material weaknesses in its internal control over financial reporting.
• The company's backlog decreased significantly from $10.4 million in 2023 to $1.1 million in 2024.
• The company's revenue decreased in 2024, primarily due to a customer migrating to a larger CDMO.
• The company's ability to continue as a going concern is uncertain.

Risks

• The company's failure to meet continued listing requirements of the NYSE American has resulted in suspension of trading and is expected to result in delisting.
• The company has not generated significant revenue and does not anticipate generating significant revenue in the near future.
• The company's financial statements have been prepared assuming that it will continue as a going concern, but there is substantial doubt about its ability to do so.
• The company has identified material weaknesses in its internal control over financial reporting.
• Certain of the company's convertible notes have restrictive covenants that prohibit it from engaging in certain financing activities.
• The company is in payment default under the terms of its convertible notes, which are secured by its assets.
• The company may be unable to attract a satisfactory strategic alternative.
• The company depends on spending and demand from its customers for its contract development and manufacturing services.
• The company's revenues have come from a limited number of customers.
• The company generally does not have long-term CDMO customer contracts.
• All of the company's manufacturing services are conducted at its facility in San Antonio, Texas, which increases its exposure to significant disruption.
• The company relies on third parties to supply most of the necessary raw materials and supplies.
• The company's manufacturing services are highly complex.
• The company's revenues and profitability are dependent upon its customers ability to receive and maintain regulatory approval for their product candidates.
• The company's use of hazardous and biological materials could result in it being liable for damages.
• Certain members of the company's management team serve as executive officers of the entity that owns Elusys Therapeutics, which may give rise to potential conflicts of interest.
• It may be difficult to enforce a judgment of a U.S. court against one of the company's directors who resides outside of the U.S.
• The company may incur substantial liabilities in connection with its CDMO services.
• Failure to comply with existing and future regulatory requirements for the company's CDMO could adversely affect its business.
• Any failure to maintain the security of information relating to the company's customers, employees and suppliers could expose it to litigation.
• The company's operating results may be adversely affected by fluctuations in foreign currency exchange rates.
• The company could be adversely affected by violations of U.S. and worldwide anti-bribery laws.
• The company has limited protection for its intellectual property.
• The company may be found to infringe upon third-party intellectual property rights of others.
• Changes in general economic conditions, geopolitical conditions, trade policies, monetary policies and other factors beyond the company's control may adversely impact its business.
• The company may not successfully effect its intended expansion.
• The company's stock price has fluctuated in the past, has recently been volatile and may be volatile in the future.
• The company relies on key executive officers and scientific and medical advisors.
• If the company is unable to hire additional qualified personnel, its ability to grow its business may be harmed.
• The company is a smaller reporting company, and it cannot be certain if the reduced reporting requirements applicable to smaller reporting companies will make its common stock less attractive to investors.
• The possible issuance of common stock subject to options, restricted stock units, and warrants may dilute the interests of stockholders.
• The company has additional securities available for issuance, which, if issued, could adversely affect the rights of the holders of its common stock.
• Certain provisions of the Delaware General Corporation Law, its bylaws and stockholder rights plan may have anti-takeover effects.
• The company's second amended and restated bylaws provide that the Court of Chancery of the State of Delaware will be the exclusive forum for certain types of state actions that may be initiated by its stockholders.
• Future sales of the company's common stock by its existing stockholders could cause its stock price to decline.
• The company's shares of common stock are from time to time thinly traded.
• Reports published by securities or industry analysts, including projections in those reports that exceed the company's actual results, could adversely affect its common stock price and trading volume.

Future Outlook

The company expects to incur significant expenses and continued losses from operations for the foreseeable future and will need to raise capital to sustain its operations. The company is considering multiple alternatives, including additional equity financings, debt financings, equipment sale leasebacks, and/or funding from partnerships or collaborations. There can be no assurance that the company will be successful in implementing these plans.

Management Comments

• The company's leadership remains committed to leveraging its scientific and technical expertise to enhance its position in the biomanufacturing sector while considering various avenues to drive long-term growth.

Industry Context

The CDMO industry is experiencing continued consolidation, resulting in a limited number of qualified, agile, and independent CDMOs with mammalian and microbial cell culture-based biologics development and manufacturing capabilities. The COVID-19 pandemic revealed a critical shortage in U.S. biomanufacturing capacity. The global cell and gene therapy clinical trials market size was valued at $9.2 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 22.3% from 2021 to 2028.

Comparison to Industry Standards

• The document mentions that Scorpius anticipates competing with established biomanufacturers including Lonza Group, WuXi AppTec, Avid Bioservices, and Catalent.
• These companies are global leaders in the CDMO space, with significantly larger revenues and market capitalization than Scorpius.
• For example, Catalent reported revenue of $4.2 billion in fiscal year 2023, while Lonza reported sales of CHF 6.2 billion in 2023.
• Scorpius's revenue of $6.2 million in 2024 is significantly lower than these industry giants.
• The document suggests that a shortage of industry capacity may minimize the risk of direct competition, but Scorpius will need to demonstrate its ability to compete on quality, service, and price to gain market share.
• Scorpius's prioritization of American-made equipment and domestic sourcing of biomanufacturing expertise may give it a competitive advantage for U.S. government contracts and biodefense assets.

Management Changes

Related Party Transactions

• The document details several related party transactions, including the acquisition and divestiture of Elusys Therapeutics, as well as convertible notes and shared services agreements with Elusys Holdings, a company controlled by Scorpius's CEO.

Stakeholder Impact

• Shareholders face the risk of delisting, stock dilution, and potential loss of investment.
• Employees face uncertainty regarding job security due to the company's financial struggles.
• Customers may be concerned about the company's ability to provide consistent and reliable services.
• Suppliers may face increased risk of non-payment.
• Creditors face increased risk of default.

Next Steps

• The company will explore strategic alternatives.
• The company will seek additional funding through equity financings, debt financings, equipment sale leasebacks, and partnerships.
• The company will work to remediate material weaknesses in its internal control over financial reporting.

Key Dates

Keywords

Scorpius Holdings, CDMO, delisting, biomanufacturing, strategic alternatives, financial results, NYSE American, contract manufacturing, biologics, internal control, going concern, revenue, losses, funding, capital